RECRUITINGPhase 3INTERVENTIONAL
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40 Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Panorama
About This Trial
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama
Who May Be Eligible (Plain English)
Who May Qualify:
1. Diagnosis of GAD per DSM-5
2. Male or female aged 18 to 74
3. HAM-A Total Score ≥20
Who Should NOT Join This Trial:
1. Certain psychiatric disorders (other than generalized anxiety disorder)
2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
4. Any clinically significant unstable illness
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. Diagnosis of GAD per DSM-5
2. Male or female aged 18 to 74
3. HAM-A Total Score ≥20
Exclusion Criteria:
1. Certain psychiatric disorders (other than generalized anxiety disorder)
2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
4. Any clinically significant unstable illness
Treatments Being Tested
OTHER
Placebo
A substance that is designed to have no therapeutic value
DRUG
MM120 (LSD D-Tartrate)
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Locations (20)
Preferred Research Partners, Inc.
Little Rock, Arkansas, United States
Psychedelic Science Institute
Los Angeles, California, United States
West Los Angeles VA Medical Center
Los Angeles, California, United States
Cenexel-CNS
Torrance, California, United States
Bradenton Research Center, Inc.
Bradenton, Florida, United States
Clinical Neuroscience Solutions, Inc
Orlando, Florida, United States
Atlanta Center for Medical Research
Atlanta, Georgia, United States
Sheppard Pratt Health System
Towson, Maryland, United States
Adams Clinical Boston
Boston, Massachusetts, United States
Princeton Medical Institute
Princeton, New Jersey, United States
University of Cincinnati Psychiatry- Anxiety Disorders Research Program
Cincinnati, Ohio, United States
Neuro-Behavioral Clinical Research, Inc.
North Canton, Ohio, United States
Austin Clinical Trial Partners
Austin, Texas, United States
Cedar Clinical Research
Murray, Utah, United States
Core Clinical Research
Everett, Washington, United States
A-shine s.r.o.
Pilsen, Czechia
Institut Neuropsychiatricke Pece (INEP)
Prague, Czechia
Psyon s.r.o.
Prague, Czechia
Cabinet Dr.Desbonnet : Résidence Saint Michel
Douai, France
Hôpital Conception, CIC Centre, bat néphrologie 3eme étage
Marseille, France